Key Summary Points {#FPar10}
==================

**Why carry out this study?**Patients with rheumatoid arthritis (RA) often continue receiving methotrexate (MTX) or other conventional synthetic disease-modifying antirheumatic drugs when initiating biologics; however, receiving an increased number of medications is associated with additive toxicities and impaired adherence to therapy.A randomized controlled trial demonstrated that outcomes are comparable in patients responding to tocilizumab (TCZ) in combination with MTX who subsequently discontinue or continue MTX; however, the frequency of such therapy changes in routine clinical practice and whether TCZ can decrease the need for concomitant MTX remains unknown.We examined MTX discontinuation and dose decreases in patients with RA initiating TCZ in a real-world observational registry.**What was learned from this study?**In this real-world population of patients with RA, a substantial proportion of patients were able to discontinue or decrease their dose of MTX over 6 months after TCZ initiation, and demonstrated improvements in disease activity and patient-reported outcomes, with similar changes observed at 12 months.These results suggest that discontinuation or decreases in MTX dose after TCZ initiation are common in real-world practice.

Introduction {#Sec1}
============

Rheumatoid arthritis (RA) is a chronic autoimmune disease that is characterized by joint swelling, stiffness, and pain and progressive destruction of synovial joints \[[@CR1]\]. Without prompt and effective disease-suppressing therapy, joint damage and disability result \[[@CR1], [@CR2]\]. Conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) are the recommended first-line treatment for patients with RA, with methotrexate (MTX) being the most frequent choice of initial csDMARD \[[@CR2], [@CR3]\]. However, a substantial proportion of patients with RA have an inadequate response to or are intolerant of MTX \[[@CR2], [@CR4]--[@CR6]\].

In patients with an inadequate response to csDMARDs, addition of another csDMARD or a biologic is recommended \[[@CR2], [@CR3]\]. In most cases, a biologic is initiated as combination therapy with the initial csDMARD \[[@CR2], [@CR3]\]; however, receiving an increased number of medications is associated with additive toxicities and impaired adherence to therapy \[[@CR7]--[@CR10]\], which has been suggested to be a substantial problem in patients with RA \[[@CR11], [@CR12]\].

Tocilizumab (TCZ) is a monoclonal antibody that blocks the interleukin-6 (IL-6) receptor and is approved for the treatment of RA in patients who have had an inadequate response to csDMARDs \[[@CR13]\]. TCZ is approved for use as monotherapy or in combination with other csDMARDs. TCZ monotherapy has been shown to be more effective than MTX monotherapy and has comparable efficacy to TCZ administered in combination with either MTX or other csDMARDs \[[@CR14]--[@CR16]\].

Thus far, a randomized controlled trial of MTX withdrawal in patients responding to TCZ plus MTX demonstrated that TCZ as monotherapy was clinically noninferior to continued use of TCZ plus MTX \[[@CR17]\]. However, the frequency of such changes in therapy in the real world, and the extent to which TCZ can decrease the need for concomitant MTX use in routine clinical practice, remains unknown. Therefore, we examined MTX discontinuation and dose decreases in patients with RA initiating TCZ in a real-world setting. We also descriptively summarized disease activity and outcomes data for patients who either discontinued, decreased, or increased their dose of MTX and patients who continued a stable MTX dose.

Methods {#Sec2}
=======

Study Setting {#Sec3}
-------------

Data were obtained from the Corrona RA Registry, an ongoing, independent, prospective, observational cohort of patients with RA (NCT01402661) \[[@CR18], [@CR19]\]. Patients were recruited from 182 private and academic practice sites across 42 states in the United States, with 781 participating rheumatologists. As of June 2019, data on 52,737 patients with RA had been collected. The Corrona database includes information from 397,236 patient visits and 188,161 patient-years of follow-up observation time. The mean duration of patient follow-up is 4.5 years (median, 3.3 years).

Patient Population and Data Collection {#Sec4}
--------------------------------------

The study population included patients aged ≥ 18 years with RA enrolled in the Corrona RA registry who initiated TCZ while maintaining an existing MTX regimen at TCZ initiation and had a follow-up visit at 6 months (± 3 months) after initiation without discontinuation of TCZ. Secondary analysis included patients with a 12-month (± 3 months) follow-up visit without discontinuation of TCZ. Patients must have had a valid MTX dose recorded at the time of TCZ initiation and follow-up. Patients were stratified by weekly MTX dose at the time of TCZ initiation (≤ 10 mg, \> 10 to ≤ 15 mg, \> 15 to ≤ 20 mg, \> 20 mg). Data from Corrona were collected from physician and patient questionnaires completed during routine clinical encounters that occurred over the study period. Data within Corrona that were recorded at the time of clinical encounter have been described previously and include patient demographics, clinical characteristics, history of comorbidities, current and prior medication use, clinical disease activity measures, and patient-reported outcome (PRO) measures \[[@CR18]\].

Ethics approvals for this study were obtained from a central institutional review board (IRB; New England Independent Review Board No. 120160610). For academic investigative sites that did not receive a waiver to use the central IRB, full board approval was obtained from the respective governing IRBs and documentation of approval was submitted to the sponsor prior to initiating any study procedures. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.

Study Design and Outcomes {#Sec5}
-------------------------

This was a retrospective, observational study to evaluate the patterns of MTX use after initiation of TCZ in patients with RA. The primary outcome was the proportion of patients with changes in MTX use (discontinuation or dose escalation or decrease ≥ 5 mg) from baseline to 6 months (± 3 months). Secondary outcomes included the proportion of patients with changes in MTX use from baseline to 12 months (± 3 months). Mean changes in disease activity and PRO measures at 6 and 12 months were also described. Disease activity measures included Clinical Disease Activity Index (CDAI), Disease Activity Score in 28 joints (DAS28), tender and swollen joint counts, and physician global assessment. PROs included patient global assessment; modified Health Assessment Questionnaire (mHAQ); and patient-reported pain, fatigue, and morning stiffness.

Statistical Analysis {#Sec6}
--------------------

Baseline demographics, clinical characteristics, and treatment history were described for the overall cohort. Changes in MTX use were assessed in the overall population and in groups stratified by baseline MTX dose (≤ 10 mg, \> 10 to ≤ 15 mg, \> 15 to ≤ 20 mg, \> 20 mg). Changes from baseline in disease activity measures and PROs were summarized descriptively for the overall cohort and in groups stratified by MTX discontinuation or dose change at the 6- or 12-month follow-up visit.

Results {#Sec7}
=======

Study Population {#Sec8}
----------------

Of 2358 patients with RA who initiated TCZ, 861 continued their existing MTX regimen at TCZ initiation; of those patients, 444 had a 6-month follow-up visit without discontinuation of TCZ and had MTX dose information available at TCZ initiation and follow-up and thus were included in the primary analysis (Fig. [1](#Fig1){ref-type="fig"}a). At baseline, 68 patients (15.3%) were receiving MTX ≤ 10 mg, 110 (24.8%) were receiving \> 10 to ≤ 15 mg, 186 (41.9%) were receiving \> 15 to ≤ 20 mg, and 80 (18.0%) were receiving \> 20 mg (Fig. [1](#Fig1){ref-type="fig"}b). For the secondary analysis, there were 311 eligible patients with a 12-month follow-up visit; of these patients, at baseline, 45 (14.5%) were receiving MTX ≤ 10 mg, 78 (25.1%) were receiving \> 10 to ≤ 15 mg, 134 (43.1%) were receiving \> 15 to ≤ 20 mg, and 54 (17.4%) were receiving \> 20 mg (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Patient disposition. **a** Study population selection. **b** Baseline MTX dose distribution among patients included in the 6-month (primary) and 12-month (secondary) analyses. ^a^Patients must have had valid MTX dose information available and must have not been receiving other csDMARDs at TCZ initiation. ^b^Patients remaining on MTX at follow-up must have had valid MTX dose information available at the follow-up visit. *csDMARD* conventional synthetic disease-modifying antirheumatic drug, *MTX* methotrexate, *RA* rheumatoid arthritis, *TCZ* tocilizumab

Patient Baseline Demographics and Clinical Characteristics {#Sec9}
----------------------------------------------------------

Patient baseline demographics, clinical characteristics, and treatment history are described in Table [1](#Tab1){ref-type="table"}. Overall, of the 444 patients with a 6-month follow-up visit who met the inclusion criteria for the primary analysis, 82.7% were female, 83.7% were white, and the majority (76.4%) were overweight or obese (Table [1](#Tab1){ref-type="table"}). The mean (SD) age was 57.3 (12.7) years and mean (SD) disease duration was 11.6 (9.3) years. More than half of the patients (54.1%) had not received csDMARDs other than MTX, and the majority (94.1%) had received ≥ 1 prior biologic. The mean (SD) MTX dose at baseline was 17.7 (5.8) mg. The mean (SD) CDAI score was 24.0 (15.4), and the majority of patients (89.8%) reported experiencing morning stiffness.Table 1Baseline demographics, clinical characteristics, treatment profile, and disease activity for patients with RA who initiated TCZ with MTXCharacteristicsAll TCZ initiators (*N* = 444)Age, mean (SD), years57.3 (12.7)Female, *n* (%)367 (82.7)Race, *n* (%) White369 (83.7) Black21 (4.8) Asian11 (2.5) Other40 (9.1)Smoking status, *n* (%) Current67 (15.2) Previous130 (29.5) Never244 (55.3)Weight, mean (SD), lb185.5 (50.3)BMI category, *n* (%) Normal/underweight (\< 25 kg/m^2^)105 (23.6) Overweight (≥ 25 to \< 30 kg/m^2^)131 (29.5) Obese (≥ 30 kg/m^2^)208 (46.8)Insurance, *n* (%)^a^ Private338 (76.1) Medicaid22 (5.0) Medicare158 (35.6) None4 (0.9)Disease duration, mean (SD), years11.6 (9.3)History of comorbidities, *n* (%) Hypertension131 (29.5) Diabetes49 (11.0) Malignancy^b^35 (7.9) Cardiovascular disease^c^160 (36.0)No. of prior non-MTX csDMARDs, *n* (%)^d,e^ 0240 (54.1) 1109 (24.5) ≥ 295 (21.4)No. of prior biologics, *n* (%)^d,f^ 026 (5.9) 1123 (27.7) ≥ 2295 (66.4)Current prednisone use, *n* (%)158 (35.6) Prednisone dose, mean (SD), mg^g^7.1 (5.4)MTX dose, mean (SD), mg17.7 (5.8)CDAI score, mean (SD)24.0 (15.4)DAS28, mean (SD)4.3 (1.6)Tender joint count (0--28), mean (SD)8.8 (8.1)Swollen joint count (0--28), mean (SD)6.3 (6.2)Physician global assessment (VAS 0--100), mean (SD)38.5 (22.2)Patient global assessment (VAS 0--100), mean (SD)50.2 (25.5)mHAQ, mean (SD)0.6 (0.5)Patient pain (VAS 0--100), mean (SD)52.3 (26.2)Patient fatigue (VAS 0--100), mean (SD)55.0 (27.9)Morning stiffness present, *n* (%)368 (89.8)Morning stiffness duration, mean (SD), h^h^1.9 (3.2)*BMI* body mass index, *CABG* coronary artery bypass grafting, *CDAI* Clinical Disease Activity Index, *CHF* congestive heart failure, *csDMARD* conventional synthetic disease-modifying antirheumatic drug, *CV* cardiovascular, *DAS28* Disease Activity Score in 28 joints, *mHAQ* modified Health Assessment Questionnaire, *MTX* methotrexate, *RA* rheumatoid arthritis, *TCZ* tocilizumab, *VAS* visual analog scale^a^Totals may not add up to 100% since patients may have had \> 1 type of insurance^b^Malignancy includes breast cancer, lung cancer, lymphoma, skin cancer (melanoma and squamous cell), and other cancers^c^History of cardiovascular disease includes history of hypertension, hyperlipidemia, cardiac revascularization procedure (CABG, stent, angioplasty), ventricular arrhythmia, cardiac arrest, myocardial infarction, acute coronary syndrome, unstable angina, other coronary artery disease, CHF (with and without hospitalization), stroke, transient ischemic attack, other CV, deep vein thrombosis, peripheral arterial disease, peripheral arterial thrombosis, urgent peripheral revascularization, peripheral ischemia/gangrene, pulmonary embolism, carotid artery disease, and hemorrhage^d^Including past and current therapies^e^csDMARDs: hydroxychloroquine, leflunomide, sulfasalazine, azathioprine, minocycline, and cyclosporine^f^Biologics: adalimumab, etanercept, certolizumab pegol, golimumab, infliximab, anakinra, sarilumab, abatacept, rituximab, and tofacitinib^g^Among prednisone users^h^Among those experiencing morning stiffness

Changes from Baseline in MTX Use and Disease Activity at 6 Months {#Sec10}
-----------------------------------------------------------------

Changes in MTX use, including discontinuation and dose decrease of ≥ 5 mg, were observed at 6 months after TCZ initiation. Of the 444 patients initiating TCZ, 139 (31.3%) discontinued or decreased their dose of MTX by ≥ 5 mg at 6 months, 269 patients (60.6%) did not change their dose, and 36 (8.1%) increased their dose by ≥ 5 mg (Fig. [2](#Fig2){ref-type="fig"}). The overall mean (SD) change in MTX dose at 6 months was − 16.2 (6.0) mg in patients who discontinued MTX, − 6.4 (4.6) mg in patients who decreased their MTX dose and − 3.0 (7.5) mg across all patients. Across baseline MTX dose groups, the proportion of patients who discontinued or decreased their dose of MTX ranged from 28.2 to 40.0% (Fig. [2](#Fig2){ref-type="fig"}). Improvements in disease activity and PROs were observed at 6 months in patients who discontinued, decreased, maintained, or increased their dose of MTX (Table [2](#Tab2){ref-type="table"}).Fig. 2Changes in MTX dose at 6 months among patients with RA who initiated TCZ with MTX, stratified by baseline MTX dose. *MTX* methotrexate, *RA* rheumatoid arthritis, *TCZ* tocilizumabTable 2Changes in disease activity and PROs^a^ at 6 months in patients with RA who initiated TCZ with MTXAll patients (*N* = 444)Discontinued MTX (*n* = 72)Decreased MTX dose (*n* = 67)No change in MTX dose (*n* = 269)Increased MTX dose (*n* = 36)CDAI− 7.8 (14.3)− 5.5 (13.1)− 7.1 (13.6)− 8.4 (14.7)− 9.8 (15.2)DAS28− 1.2 (1.7)− 1.0 (1.7)− 1.1 (1.5)− 1.3 (1.6)− 0.9 (2.4)Tender joint count− 3.2 (7.9)− 1.3 (7.1)− 1.8 (7.5)− 3.8 (8.1)− 4.2 (7.6)Swollen joint count− 2.6 (5.6)− 2.2 (5.2)− 2.2 (5.1)− 2.7 (5.8)− 3.1 (6.1)Physician global assessment− 13.1 (23.1)− 13.3 (23.4)− 17.0 (20.7)− 11.8 (23.4)− 16.2 (24.0)Patient global assessment− 7.6 (25.9)− 6.4 (25.9)− 13.5 (28.5)− 6.4 (25.0)− 7.3 (26.4)mHAQ− 0.1 (0.4)− 0.1 (0.4)− 0.1 (0.4)0 (0.4)− 0.2 (0.5)Patient pain− 7.3 (24.4)− 6.2 (23.7)− 8.2 (24.8)− 7.0 (24.3)− 10.8 (26.2)Patient fatigue− 6.3 (26.6)− 7.3 (26.5)− 8.6 (30.7)− 5.0 (26.3)− 10.3 (20.2)Morning stiffness present, *n* (%)− 29 (7.1)− 6 (9.4)− 5 (8.2)− 17 (6.8)− 1 (3.0)Morning stiffness duration, h− 0.1 (3.7)− 0.7 (2.8)0 (2.1)− 0.1 (3.8)0.3 (6.1)*CDAI* Clinical Disease Activity Index, *DAS28* Disease Activity Score in 28 joints, *mHAQ* modified Health Assessment Questionnaire, *MTX* methotrexate, *PRO* patient-reported outcome, *RA* rheumatoid arthritis, *TCZ* tocilizumab^a^Changes in disease activity and PRO measures are presented as mean (SD) unless otherwise indicated

Changes from Baseline in MTX Use and Disease Activity at 12 Months {#Sec11}
------------------------------------------------------------------

Changes in MTX use were also observed at 12 months after initiation of TCZ. Of the 311 patients with a 12-month follow-up visit, 119 (38.3%) discontinued or decreased their dose of MTX by ≥ 5 mg, 156 patients (50.2%) did not change their dose, and 36 (11.6%) increased their dose by ≥ 5 mg (Fig. [3](#Fig3){ref-type="fig"}). The overall mean (SD) change in MTX dose at 12 months was − 17.3 (5.9) mg in patients who discontinued MTX, − 7.7 (6.2) mg in patients who decreased their MTX dose and − 3.8 (13.7) mg across all patients. Across baseline MTX dose groups, the proportion of patients who discontinued or decreased their dose of MTX ranged from 35.6 to 42.6% (Fig. [3](#Fig3){ref-type="fig"}). Improvements in disease activity and PROs were observed at 12 months in patients who discontinued, decreased, maintained, or increased their dose of MTX (Table [3](#Tab3){ref-type="table"}).Fig. 3Changes in MTX dose at 12 months among patients with RA who initiated TCZ with MTX, stratified by baseline MTX dose. *MTX* methotrexate, *RA* rheumatoid arthritis, *TCZ* tocilizumabTable 3Changes in disease activity and PROs^a^ at 12 months in patients with RA who initiated TCZ with MTXAll patients (*N* = 311)Discontinued MTX (*n* = 67)Decreased MTX dose (*n* = 52)No change in MTX dose (*n* = 156)Increased MTX dose (*n* = 36)CDAI− 8.0 (15.0)− 8.6 (14.8)− 7.9 (12.4)− 7.7 (14.3)− 8.1 (21.3)DAS28− 1.2 (1.8)− 1.0 (1.5)− 1.1 (1.5)− 1.4 (1.8)− 1.0 (2.7)Tender joint count− 3.1 (8.3)− 3.8 (6.9)− 2.4 (6.0)− 3.1 (9.2)− 3.1 (9.9)Swollen joint count− 2.6 (5.8)− 2.2 (6.4)− 2.7 (5.1)− 2.6 (4.9)− 2.8 (8.6)Physician global assessment− 14.9 (22.4)− 16.0 (21.8)− 18.2 (21.6)− 13.1 (21.8)− 15.8 (27.4)Patient global assessment− 9.3 (25.1)− 9.7 (24.9)− 9.6 (29.4)− 9.6 (22.0)− 6.5 (31.5)mHAQ0 (0.4)0 (0.4)− 0.1 (0.4)0 (0.3)− 0.1 (0.6)Patient pain− 8.0 (25.3)− 8.0 (26.9)− 6.8 (29.2)− 8.3 (22.1)− 8.6 (30.4)Patient fatigue− 8.5 (25.9)− 10.8 (24.9)− 5.9 (31.4)− 7.8 (24.3)− 11.3 (26.9)Morning stiffness present, *n* (%)− 18 (6.3)− 1 (1.7)− 3 (6.5)− 14 (9.6)0 (0)Morning stiffness duration, h− 0.3 (2.6)− 0.3 (3.1)0.1 (1.5)− 0.4 (2.8)− 0.3 (1.3)*CDAI* Clinical Disease Activity Index, *DAS28* Disease Activity Score in 28 joints, *mHAQ* modified Health Assessment Questionnaire, *MTX* methotrexate, *PRO* patient-reported outcome, *RA* rheumatoid arthritis, *TCZ* tocilizumab^a^Changes in disease activity and PRO measures are presented as mean (SD) unless otherwise indicated

Discussion {#Sec12}
==========

Patients with an inadequate response to csDMARDs are frequently treated with a biologic agent. In most cases, the biologic is administered in combination with the existing csDMARD, which is often MTX \[[@CR2], [@CR3]\]. However, adherence to such combination therapy may be adversely affected by the increased medication burden and risk of additive toxicities \[[@CR7]--[@CR10]\]. Thus, research is being devoted to understanding treatment patterns and outcomes with biologics administered as monotherapy.

Currently, results on the use of biologic monotherapy stem primarily from clinical trials. In particular, TCZ monotherapy in US-based randomized controlled trials was demonstrated to have superior efficacy compared with MTX monotherapy \[[@CR16]\] and tumor necrosis factor (TNF) inhibitor monotherapy \[[@CR20]\] and comparable efficacy to TCZ plus MTX combination therapy \[[@CR15]\]. These findings are also supported by trials in Japan \[[@CR21]\] and Europe \[[@CR14]\]. However, there are limited real-world data in the United States regarding whether TCZ can reduce the need for concomitant MTX.

The present analysis aimed to corroborate trial information with real-world evidence by describing the patterns of MTX discontinuation or dose decreases after the initiation of TCZ. We observed that many patients were able to decrease their dose or discontinue use of MTX at both 6 and 12 months after initiating TCZ. These changes were independent of baseline MTX dose, and improvements in disease activity and functionality outcomes were observed in patients who discontinued or decreased MTX.

Our findings are supported by data from additional real-world studies demonstrating discontinuation of MTX in patients with RA after initiation of TCZ plus MTX combination therapy. The Japanese FIRST Bio study demonstrated that, of patients initiating TCZ with concomitant MTX, 19.3% discontinued MTX by week 52, and the overall mean MTX dose decreased from 9.1 mg to 6.4 mg per week \[[@CR22]\]. These results are comparable to the present study, which demonstrated that 21.5% of patients discontinued MTX at 12 months and the overall mean change in MTX dose at 12 months was -- 3.8 (13.7) mg. Additionally, in a multinational observational study of patients with RA initiating TCZ, 47.8% received concomitant MTX at baseline, whereas 43.0% received concomitant MTX at month 6; of patients with a change in MTX dose, the mean (SD) dose change was − 2.9 (5.5) mg per week \[[@CR23]\]. Notably, patients in the multinational study had higher baseline disease activity than patients in our study. The present analysis demonstrated that 16.2% of patients discontinued MTX at 6 months and the overall mean (SD) dose change at 6 months was − 3.0 (7.5) mg.

There are limited data on the efficacy and effectiveness of TCZ after MTX dose decrease or discontinuation. The COMP-ACT trial demonstrated that discontinuation of MTX was noninferior to continuation of MTX for the maintenance of low disease activity (LDA) over 16 weeks \[[@CR17]\] in patients with RA who had achieved LDA within 24 weeks of initiating TCZ plus MTX. The Japanese T-ReX trial further demonstrated the clinical feasibility of MTX discontinuation for maintenance of LDA in patients who sustained LDA for ≥ 12 weeks while receiving TCZ plus MTX combination therapy \[[@CR24]\]. Our study sought to address the need for data on the real-world effectiveness of TCZ after MTX dose decrease or discontinuation by evaluating changes in clinical disease activity measures and PROs at both 6 and 12 months in patients seen in routine clinical practice in the United States. The descriptive data provided did not show any apparent increase in disease activity in patients who discontinued or decreased their dose of MTX.

In patients receiving anti-TNF antibodies (aTNFs), discontinuation of MTX is contraindicated because MTX inhibits antidrug antibody formation against aTNFs, thereby resulting in loss of efficacy \[[@CR25]\]. However, there is reason to believe that discontinuation of MTX may be more successful with therapies that inhibit IL-6, such as TCZ. It has been demonstrated that MTX itself inhibits IL-6 \[[@CR26]\], making it possible to posit that, in patients responding to TCZ plus MTX, the relative contribution of IL-6 inhibition from TCZ is far greater than it is from MTX. Thus, the loss of IL-6 inhibition upon MTX discontinuation may have a lesser impact on response in patients receiving TCZ plus MTX than in those receiving aTNF plus MTX.

A strength of this real-world study is the large number of patients included, which was possible through use of the Corrona RA registry. Corrona is the largest RA registry in the United States that collects data directly from both physicians and patients at the time of a routine clinical encounter. This design allowed us to evaluate outcomes at multiple time points. Additionally, rheumatology practices from across the United States participate in the Corrona RA registry, including practices in both rural and urban areas and academic and private settings, which provides access to patients of diverse socioeconomic backgrounds. It has been shown that Medicare beneficiaries with RA in the Corrona Registry have a comparable demographic profile and comorbidity burden to the overall US Medicare RA population, which supports the generalizability of the findings from the Corrona RA Registry \[[@CR19]\].

As with other observational studies, this study has some limitations. As is the case with all registry data, there is the possibility of a channeling bias for the choice of therapeutic agent as participants are not randomly assigned to different treatments. Additionally, because the goal of this analysis was to examine changes in MTX use after TCZ initiation in a real-world setting and not to evaluate associations between initial MTX dose and subsequent changes in MTX dose or discontinuation, this study presented descriptive data without matching patients or adjusting for statistical imbalances between the different patient groups; future studies would be needed to examine such associations. Patients who discontinued TCZ for any reason were excluded; thus, our primary analysis demonstrated the changes in MTX dose for patients who tolerated TCZ treatment and did not discontinue for 6 months, while the secondary analysis demonstrated outcomes for patients who did not discontinue for 12 months. Therefore, these findings may not be generalizable for patients who discontinue TCZ before 6 or 12 months.

Conclusions {#Sec13}
===========

In this real-world population of patients with RA, a substantial proportion of patients initiating TCZ were able to discontinue or decrease their dose of MTX over 6 months after TCZ initiation, with similar changes in MTX dose at 12 months. Discontinuation or dose decrease of MTX was observed across all baseline MTX doses. Disease activity and PRO improvements were observed at 6 or 12 months in patients who decreased or discontinued MTX. These results suggest that discontinuation or decreases in the dose of MTX after initiation of TCZ are common in real-world practice.
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